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The essential features of hepatic protoporphyria, namely inhibition of ferrochelatasei accumulation of
protoporphyrin and stimulation of 5-aminolevulinic a id syuthase (ALA-S) were all obtained by treating 
chicken hepatocytes in culture with small doses of N-methylprotoporphyrin. Both N-methylprotopor- 
phyrin and succinyl-acetone, another inhibitor of heme biosynthesis, timulated ALA-S when given on 
their own and also enhanced the stimulation of ALA-S caused by phenobarbital. 
Porphyria Heme N-Methylprotoporphyrin J-Aminolevulinic acid synthase 
3,5-Diethoxycarbonyl-1,Cdihydrocollidine (Liver) 
1. INTRODUCTION repression of ALA-S and, therefore, to increased 
ALA-S activity [3-$71. 
3,5Diethoxycarbonyl-1 &lihydrocollidine @DC) 
has long been known to cause a marked inhibition 
of hepatic ferrochelatase (EC 4.99.1. I), leading to 
accumulation of protoporphyrin and to the bio- 
chemical picture of hepatic protoporphyria [ 11. 
Stimulation of the first and rate-limiting enzyme of 
the pathway, S-aminolevulinic acid synthase, 
ALA-S (EC 2.3.1.37) is also observed after DDC 
treatment [2], an effect which contributes signif- 
icantly to the accumulation of protoporphyrin [3]. 
DDC has also been reported to potentiate marked- 
ly the stimulation of ALA-S activity caused in the 
liver by a large number of lipid-soluble drugs, in- 
cluding phenobarbital [4-61. It has been proposed 
that these effects of DDC on ALA-S activity may 
be secondary to the inhibition of ferrochelatase, 
since the decreased heme formation thus resulting 
would lead to diminished heme-mediated feedback 
In [8,9], a powerful inhibitor of ferrochelatase 
has been extracted from the liver of animals 
treated with DDC. The inhibitor has been iden- 
tified as N-methylprotoporphyrin [lo-121 and has 
been shown to originate from metabolic transfer of 
the intact 4-methyl group of DDC to one of the 
pyrrole nitrogens of the porphyrin moiety of liver 
heme [12-141. Confirmation of the inhibitory ef- 
fect on ferrochelatase has been obtained using syn- 
thetic N-methylated porphyrins [ 10,15- 171. 
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N-Methylprotoporphyrin was shown to share 
the ability of DDC to markedly inhibit fer- 
rochelatase activity in chick embryo liver cell 
culture (171. However, unlike DDC, N- 
methylprotoporphyrin did not elevate ALA-S 
when measured 12 h after addition to the 
hepatocyte culture. It was therefore concluded that 
ZV-methylprotoporphyrin-induced ferrochelatase 
inhibition was not accompanied by enhanced 
ALA-S activity. 
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We have now investigated the effect of authentic 
ZV-methylprotoporphyrin on ALA-S activity at ad- 
ditional time periods in cultured chicken 
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hepatocytes. We found that inhibition of ferro- 
chelatase, accumulation of protoporphyrin and 
compensatory stimulation of ALA-S are all ob- 
tained 5 h after addition of the alkylated por- 
phyrin, in keeping with the concept that conver- 
sion of liver heme to the inhibitory N- 
methylprotoporphyrin is the primary biochemical 
mechanism by which DDC induces hepatic por- 
phyria. The effect of succinyl-acetone, another in- 
hibitor of heme biosynthesis [18,191, has also been 
investigated. 
2. MATERIALS AND METHODS 
2.1. Chick embryo liver cell cultures 
The details of the cell culture technique have 
been described [20,21]. The hepatocytes were 
maintained in serum-free Waymouth MD705/1 
medium supplemented with penicillin G, strep- 
tomycin, insulin and thyroxine, in 10 cm diam. 
disposable plastic dishes containing 15 ml 
medium. After an initial incubation of 24 h, the 
medium was discarded, replaced with fresh 
medium and the various drugs added. Phenobar- 
bital sodium and succinyl-acetone were added 
dissolved in saline (20 pi/dish) and N-methylproto- 
porphyrin (free acid), dissolved in 95% ethanol (20 
@dish), control dishes receiving the appropriate 
solvent only. After a further incubation of either 
5 h or 24 h, the medium was discarded and 5 ml of 
a solution containing 0.9% NaCl, 0.01 M Tris- 
HCl and 0.5 mM EDTA at pH 7.4 were added to 
each dish. The cells were removed by scraping with 
a rubber policeman and cells from two identically 
treated dishes were combined and centrifuged (500 
x g) for 5 min. The cell pellet was suspended in 
0.5-2 ml ice-cold NaCl-Tris-EDTA buffer and 
homogenized using a Potter-type homogenizer. 
Homogenates for ferrochelatase assay were 
prepared in ice-cold Tris-HCl buffer (pH 8.2) us- 
ing a Polytron homogenizer. 
2.2. Measurement of enzyme activities 
Ferrochelatase activity of the cell homogenates 
was measured by the pyridine hemochromogen 
method, using mesoporphyrin and iron as 
substrates, as in [17]. ALA-S activity was 
measured by a slight modification of an isotopic 
technique [22]: cell homogenates (equivalent to 
0.5-1.5 mg protein) were incubated for 30 min at 
128 
38°C in air but without shaking, in the presence of 
Tris-HCl buffer (63 mM), glycine (80 mM), ED- 
TA (8 mM), pyridoxal-5 ‘-phosphate (0.4 mM) 
and [2,3-‘4C]succinate (0.37 mM), in a total 
volume of 0.5 ml, at pH 7.2. 5-Aminolevulinic 
acid dehydratase (EC 4.2.1.24) was assayed as in 
[23], using the Ehrlich reagent, 2 M with respect o 
HClO4 [24], to estimate the porphobilinogen 
formed. 
2.3. Estimation of porphyrins and of protein 
Total cell porphyrins were extracted into 20 vol. 
0.9 N HC104-ethanol (1: 1) and measured 
fluorimetrically using a Turner instrument 
calibrated with appropriate standards of copropor- 
phyrin III [25]. Protein was assayed by a modifica- 
tion [26] of the Lowry [27] procedure. 
2.4. Source of special chemicals 
N-Methylprotoporphyrin dimethyl ester was 
prepared from protoporphyrin IX dimethylester as 
in [13] except that the reaction was carried out at 
100°C for 4 h. The concentration of the 
methylester was first determined using an #!?mM = 
127.8 [28] for its Soret absorption in CHC13; the 
ester was then hydrolysed with 6 M HCl for 16 h 
and the resulting free acid was dried under Nz, 
dissolved in 95% ethanol and stored in the dark at 
- 70°C. Succinyl-acetone(4,ddioxoheptanoicacid) 
was obtained from Calbiochem-Behring (La Jolla, 
CA 92037). 
3. RESULTS AND DISCUSSION 
When chicken hepatocytes in culture were 
treated for 5 h with increasing amounts of N- 
methylprotoporphyrin, a very pronounced inhibi- 
tion of ferrochelatase was found and even the 
lowest dose of alkylated porphyrin (6 ng/ml of 
medium) produced maximal or nearly maximal 
loss of enzyme activity (fig.1). A marked increase 
in cellular porphyrins (mostly protoporphyrin as 
determined by fluorescence spectroscopy) was seen 
and, in addition, a significant stimulation of ALA- 
S. At higher concentrations of N-methylprotopor- 
phyrin further increases in ALA-S activity were 
found and these were accompanied by correspond- 
ing further increases in cell porphyrin concentra- 
tion (fig.1). A stimulation of ALA-S activity was 
also seen 5 h after treating hepatocytes with 
number I,2 
ng N-Me PROTOPOKPHY~iN/ml medwm 
Fig. I. Effect of increasing doses of N- 
methylprotoporphyrin on ALA-S and ferrochdatase 
activities and on total porphyrin content of cultured 
hepatocytes, 5 h after treatment. Average f SEM of at 
least 3 observations or average of 2 observations: * p < 
0.01; ** p < 0.001, when compared with corresponding 
control value. 
FEBS LETTERS August 1983 
succinyl-acetone (fig.2), another inhibitor of heme 
biosynthesis. In this case the expected loss of ac- 
tivity of 5-aminolev~inic acid dehydratase, the 
specific target of succinyl-acetone inhibition [19], 
could also be demonstrated (fig.2), but no rise in 
cellular porphyrins was found. 
N-Methylprotoporphyrin and succinyl-acetone 
not only stimulated ALA-S when given on their 
own but also enhanced the stimulation of ALA-S 
activity caused by a lipid-soluble inducer, 
phenobarbital (table 1). Succinyl-acetone was 
more effective than N-methylprotoporphyrin in 
both respects; in addition, a stimulation of ALA-S 
was still observed 24 h after addition of succinyl- 
acetone, whereas a depression of ALA-S activity 
(below the level of the corresponding control 
value) was seen 24 h after N-methylprotoporphy- 
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Fig.2. Effect of increasing doses of succinyl-acetone on 
the activities of ALA-S and S-aminolevulinic acid 
dehydratase and on total porphyrin content of cultured 
hepatocytes, 5 h after treatment. Single observations 
each obtained with pooled hepatocytes from two 
identically treated dishes. 
rin (table 1). This suggests that N-methylprotopor- 
phyrin may possess two opposite effects on ALA- 
S, one leading to stimulation, the other to depres- 
sion of synthase activity, the first effect pre- 
dominating at the early time point. The mechanism 
by which N-methylprotoporphyrin causes a late in- 
hibition of ALA-S is not known. 
The finding that two inhibitors of heme biosyn- 
thesis can enhance the stimulation of ALA-S caus- 
ed by phenobarbital is compatible with the concept 
[4-7,29-321 that when the negative feedback con- 
trol exercised by heme on ALA-S is diminished, 
the enzyme becomes more sensitive to stimulation 
by lipid-soluble drugs. This work also indicates 
that inhibition of heme bios~thesis can alone lead 
to a compensatory stimulation of ALA-S (fig. 1,2; 
table 1). While an inducer with high lipid-solubility 
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Table 1 
Effect of N-methyl protoporphyrin (N-MePP), succinyl-acetone (SA) and sodium phenobarbital 
(PB) on the activity of ALA-S and total porphyrin content of chicken hepatocytes in culture 
Drug added and initial 
concentration 
(ug/ml medium) 
ALA-S Total porphyrins 
(pmol ALA. min-’ . mg prot.-‘) (pmol/mg protein) 
5 h Treatment 
Control 12.9 f 1.1 (18) 19.0 f 2.6 (21) 
N-MePP (0.2) 30.6 + 2.8 (ll)b 438.0 f 33.5 (12)b 
SA (115.0) 45.6 f 2.0 ( 6)b 16.6 * 3.9 ( 7) 
PB (50.0) 19.5 f 1.1 (lo)b 15.5 +_ 2.7 (12) 
N-MePP (0.2) + PB (50.0) 51.7 f 7.4 ( 6) 532.1 f 77 ( 8) 
SA (115.0) + PB (50.0) 66.0 f 5 ( 3)c 14.2 f 4.6 ( 4) 
24 h Treatment 
Control 8.2 f 0.87 ( 9) 18.7 f 3.8 (11) 
N-MePP (0.2) 5.3 f 0.7 ( 7)* 433.0 f 33 ( 8)b 
SA (115.0) 19.2 + 3.5 ( 3) 21.9 f 5.4 ( 3) 
a p < 0.05 
b p < 0.001, when compared with corresponding control value 
’ p 6 0.02, when compared with corresponding PB value 
Results given are averages + SEM of the number of observations in parentheses 
(e.g., phenobarbital) will enhance ALA-S induc- 
tion, its presence is not obligatory (table 1). Thus 
a state of heme depletion is a sufficient stimulus 
for induction of ALA-S [33]. 
The essential features of hepatic protopor- 
phyria, namely inhibition of ferrochelatase, ac- 
cumulation of protoporphyrin and stimulation of 
ALA-S were all obtained after addition of N- 
methylprotoporphyrin to chicken hepatocytes in 
culture; this provides strong support for the 
hypothesis that production of N- 
methylprotoporphyrin from liver heme is the 
primary mechanism by which DDC induces 
hepatic porphyria. 
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